To enhance anti-tumor activity, we inserted a PD-L1 inhibitor (iPD-L1) driven by the human cytomegalovirus (hCMV) promoter into the EP0 locus of PRV-ΔTK (Figure 3A). Here, CD274 is linked to neoplasm.